Valiant Labs Clarifies Segment Disclosure for Q2 FY26 Results
Valiant Laboratories Limited clarified its Q2 FY26 financial results, stating it operates as a single business segment as per Ind AS 108. Segment disclosure was omitted as there are no separate reportable segments. This will be disclosed from the next quarter onwards.
This is a clarification on a reporting requirement and does not introduce new material information that would significantly impact the company's valuation or operations.
The announcement is a clarification regarding financial reporting and does not contain new positive or negative financial information.
Valiant Laboratories Limited has responded to a query from the National Stock Exchange of India (NSE) regarding the absence of segment disclosure in its audited financial results for the quarter and half-year ended September 30, 2025.
The company explained that its operations, along with its wholly-owned subsidiary Valiant Advanced Sciences Private Limited, form a single integrated business. The Holding Company manufactures Paracetamol, while the subsidiary produces Acetic Anhydride, a key raw material for Paracetamol. The Group's Chief Operating Decision Maker (CODM) manages these operations as a single business and reviews performance on a consolidated basis.
In accordance with Ind AS 108 – Operating Segments, the Group has only one operating segment. As there are no separately identifiable reportable segments, separate segment information was not required in the previously submitted consolidated financial results. Therefore, the results did not contain segment-wise disclosure.
The company assured that from the subsequent quarter onwards, segment information will be appropriately disclosed in the notes to the financial statements submitted to the Exchange.
Akshay Gangurde, Company Secretary & Compliance Officer, signed the clarification.
What to do with a filing like this
Valiant Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Valiant Laboratories Limited. Read the original for the full detail.